

HealthTech Investor Day will focus on drawing investments to European companies and on the latest medical innovations

Meetings between European HealthTech leaders, international investors and pharmaceutical groups to be held in Paris on June 24-25, 2019. In addition, the event will feature 9 plenary meetings on economic and societal challenges facing health innovation

Paris, April 4th, 2019 – The first edition of [HealthTech Investor Day \(HTID®\)](#), an international event organized with the support of the European health innovation ecosystem, **under the High Patronage of Mr. Emmanuel MACRON**, President of the French Republic, **will take place on June 24 and 25 in Paris, France, at The Peninsula Paris**. The event will bring together the most promising European HealthTech companies (biotech, medtech and e-health), leading pharmaceutical companies and international investors specializing in health innovation.

“Europe is a land of innovation in health with many start-ups and SMEs looking for financing to make their innovations available to patients and to meet the medical challenges of tomorrow. The objective of HealthTech Investor Day (HTID) is to become a reference place for exchanges between European HealthTech companies, international investors and pharmaceutical groups. HTID wants to create the necessary synergies for the development of this industrial sector and thus enable Europe to play a central role in the global health ecosystem.” said **Maryvonne Hiance, Chairman of France Biotech**.

A program combining finance, business development and medical innovation

The two-day event will feature various roundtables and one-on-one meetings in order to offer a privileged opportunity for companies, investors and pharmaceutical groups to share and discuss their goals.

The event will also include 9 plenary meetings on topics related to reasons to invest in Europe, funding solutions for companies, best international practices, business development and health innovations. These roundtables will bring together international experts who will share their visions of the global health innovation ecosystem and challenges ahead.

This event has built up momentum and lined up strong support within the ecosystem.

- Partners -



- Support -



- Organizational support -



- Pharmaceutical companies taking part at the event -



To be continued ...

List of plenary meetings

Economy & Finance

- **European attractiveness:** The panel will look back on notable European success stories and will share best practices to ensure the sustainable growth of HealthTech companies.
- **Why invest in European HealthTech companies?** The panel will outline key incentives to invest in the European ecosystem.
- **Diversity of investments: what are the stakes?** The panel will discuss the consequences of mutualized investments, including between the U.S. and Europe, and of dual listing.

- **Synergies between business development and fundraising:** What solutions will secure growth and high-risk development?

Health & Medical Innovation

- **Healthcare in 2030: a prospective analysis of health innovation:** What are the major upcoming transformations and their impact on our health system?

- **Oncology: what will be the next breakthrough innovations?** A panel of medical experts will review new therapeutic approaches introduced by autologous CAR-T cells, anti-PD1, anti-PD-L1.

- **European Strengths in Artificial Intelligence in Healthcare:** The panel will go over the main issues and challenges of Artificial Intelligence in the health sector.

Entrepreneurship

- **Innovative start-ups & pharmaceutical groups: a winning duo?** This meeting will focus on three European successes that resulted from pharmaceutical companies and innovative HealthTech startups working together.

- **The American entrepreneurship model in healthcare sciences: what are best practices?** The panel will share American best practices for the rapid growth of HealthTech companies.

The full program and schedule are available on the event's website: www.htid-paris.com

Members of the France Biotech network who will not be in attendance will have the possibility to watch the plenary meetings live, from France Biotech's intranet.

The plenary meetings will be open to the press. Accreditation requests should be sent via email to francebiotech@alizerp.com.

About France Biotech

Created in 1997, France Biotech is a French nonprofit that brings together the country's leading innovative health companies and their expert partners (investors, lawyers, research institutes, competitiveness clusters, etc.). Its core mission is to promote health innovation in France and help the sector's start-up companies and SMEs to become successful organizations, capable of rapidly developing new therapeutic solutions. France Biotech, which championed the creation of the French Young Innovative Company (JEI) status in 2004, is advocating for the innovative health sector to be recognized as a cutting-edge industry. France Biotech is chaired by Maryvonne Hiance, and has more than 200 members. www.france-biotech.fr

Press contacts

ALIZE RP - Europe

Caroline Carmagnol / Najette Chaib/ Tatiana Vieira
francebiotech@alizerp.com
+336 64 18 99 59 / +336 47 38 90 04 / +336 31 13 76 20

France Biotech

Maryvonne Hiance
Chairman
mhiance@france-biotech.org

RooneyPartners LLC – North America

Marion Janic / Kate Barrette
mjanic@rooneyco.com / kbarrette@rooneyco.com
+1.212.223.4017 / +1.212.223.0561

For more information on HTID®, contact Sophie Villedieu (sophie.villedieu@france-biotech.org) and Nathalie Donne (nathalie.donne@shapenlink.com)